Hypericin-photodynamic therapy leads to interleukin-6 secretion by HepG2 cells and their apoptosis via recruitment of BH3 interacting-domain death agonist and caspases
Open Access
- 27 June 2013
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 4 (6) , e697
Abstract
Photodynamic therapy (PDT) has emerged as a capable therapeutic modality for the treatment of cancer. PDT is a targeted cancer therapy that reportedly leads to tumor cell apoptosis and/or necrosis by facilitating the secretion of certain pro-inflammatory cytokines and expression of multiple apoptotic mediators in the tumor microenvironment. In addition, PDT also triggers oxidative stress that directs tumor cell killing and activation of inflammatory responses. However, the cellular and molecular mechanisms underlying the role of PDT in facilitating tumor cell apoptosis remain ambiguous. Here, we investigated the ability of PDT in association with hypericin (HY) to induce tumor cell apoptosis by facilitating the induction of reactive oxygen species (ROS) and secretion of Th1/Th2/Th17 cytokines in human hepatocellular liver carcinoma cell line (HepG2) cells. To discover if any apoptotic mediators were implicated in the enhancement of cell death of HY-PDT-treated tumor cells, selected gene profiling in response to HY-PDT treatment was implemented. Experimental results showed that interleukin (IL)-6 was significantly increased in all HY-PDT-treated cells, especially in 1 μg/ml HY-PDT, resulting in cell death. In addition, quantitative real-time PCR analysis revealed that the expression of apoptotic genes, such as BH3-interacting-domain death agonist (BID), cytochrome complex (CYT-C) and caspases (CASP3, 6, 7, 8 and 9) was remarkably higher in HY-PDT-treated HepG2 cells than the untreated HepG2 cells, entailing that tumor destruction of immune-mediated cell death occurs only in PDT-treated tumor cells. Hence, we showed that HY-PDT treatment induces apoptosis in HepG2 cells by facilitating cytotoxic ROS, and potentially recruits IL-6 and apoptosis mediators, providing additional hints for the existence of alternative mechanisms of anti-tumor immunity in hepatocellular carcinoma, which contribute to long-term suppression of tumor growth following PDT.Keywords
This publication has 44 references indexed in Scilit:
- Synergistic Anti-Tumor Effects of Combination of Photodynamic Therapy and Arsenic Compound in Cervical Cancer Cells: In Vivo and In Vitro StudiesPLOS ONE, 2012
- Interleukin-10 Ablation Promotes Tumor Development, Growth, and MetastasisCancer Research, 2012
- Induction of Immune Mediators in Glioma and Prostate Cancer Cells by Non-Lethal Photodynamic TherapyPLOS ONE, 2011
- Cell Death Pathways in Photodynamic Therapy of CancerCancers, 2011
- Photodynamic Therapy of Tumors Can Lead to Development of Systemic Antigen-Specific Immune ResponsePLOS ONE, 2010
- A High-Throughput Biophotonics Instrument to Screen for Novel Ocular Photosensitizing Therapeutic AgentsInvestigative Ophthalmology & Visual Science, 2010
- Several Nuclear Events during Apoptosis Depend on Caspase-3 Activation but Do Not Constitute a Common PathwayPLOS ONE, 2009
- Interleukin-6 trans signalling enhances photodynamic therapy by modulating cell cyclingBritish Journal of Cancer, 2007
- A cytokine-mediated link between innate immunity, inflammation, and cancerJournal of Clinical Investigation, 2007
- Photodynamic therapy and anti-tumour immunityNature Reviews Cancer, 2006